89Strontium therapy of bone metastases of carcinoma of the prostatic gland

Abstract

Following a firm diagnostic and therapeutic schedule for patients with prostatic carcinoma. 89Strontium therapy was introduced for multiple metastases. Positive skeletal scintigraphy with 99mTc-EHDP induced check for affinity to Sr using 85Sr scintigraphy. Of 80 patients, multiple metastases were found in 26. Therapy with 1 mCi of 89Sr-chloride was started in 20 cases. In 8 patients, relief from severe pain appeared shortly afterward, and a further 8 it was possible to prevent the development of pain. Moderate success in 3 cases and a failure to provide relief in 1 were observed.

Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts

“…The main outcome measured in studies of these radionuclides is the degree of pain relief experienced by patients with painful metastases. One study reported a high rate of pain relief, which may have been the result of hormonal therapy that was not described in the report 28 . Other studies revealed rates of complete relief of pain ranging from 0 to 73% for patients able to be evaluated (Table 2).…”

“…21 Several clinical trials and retrospective reports on the use of 89 Sr have appeared in the literature, most relating to the treatment of prostate cancer metastases, with a smaller number relating to the treatment of metastases from breast carcinoma. [26][27][28][29][30][31][32][33][34][35][36][37] These reports have dealt with subjective effects (including pain relief and possible placebo effects), objec-tive effects (including survival), and efficacy as an adjunctive therapy.…”

“…One study reported a high rate of pain relief, which may have been the result of hormonal therapy that was not described in the report. 28 Other studies revealed rates of complete relief of pain ranging from 0 to 73% for patients able to be evaluated ( Table 2).…”

Strontium-89 Chloride in the Treatment of Bone Metastases from Breast Cancer

“…Strontium imitates calcium in vivo and therefore localizes in bone mineral, especially at sites of increased bone turnover. There is now a wealth of data to support the use of strontium-89 as an effective agent for the pain palliation and with less bone marrow toxicity than phosphorus-32 [5][6][7][8][9].…”